The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 02, 2026
Filed:
Feb. 26, 2021
Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;
Ceinge Biotecnologie Avanzate Scarl, Naples, IT;
Institut Gustave Roussy, Villejuif, FR;
Sorbonne Université, Paris, FR;
Université Paris Cité, Paris, FR;
Assistance Publique-hôpitaux DE Paris (Aphp), Paris, FR;
Maria Chiara Maiuri, Paris Cedex, FR;
Guido Kroemer, Paris Cedex, FR;
Jonathan Pol, Paris Cedex, FR;
Francesco Salvatore, Naples, IT;
Fatima De Palma, Naples, IT;
Valentina Del Monaco, Naples, IT;
INSTIT NATIONAL DE LA SANTE ET DE AL RECHERCHE MEDICALE (INSERM), Paris, FR;
Ceinge Biotecnologie Avanzate SCARL, Naples, IT;
Institut Gustave Roussy, Villejuif, FR;
Sorbonne Université, Paris, FR;
Université Paris Cité, Paris, FR;
Assistance Publique-Hôpitaux de Paris (APHP), Paris, FR;
Abstract
The present invention relates to methods and compositions for the care of breast cancer, from diagnosis to treatment management. The inventors show that LINC01087 downregulation contributes to a more aggressive phenotype of BC, and could represents a novel and promising specific biomarker for the diagnosis of triple-negative breast cancer. The inventors show that LINC01087 upregulation contributes to a less aggressive phenotype of BC, and could represents a novel and promising specific biomarker for the diagnosis of luminal BCs. The invention relates to a method comprising the steps of: i) determining the expression level of the long intergenic non-coding RNA 01087 (LINC01087) in a sample obtained from the subject, and ii) comparing the expression level determined at step i) with a predetermined reference value, wherein detecting difference between the expression level determined at step i) and the predetermined reference value is indicative of an aggressive TNBC or less aggressive luminal BCs.